IJMPR 2024, 8(1), 15-23

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 5.273

REVIEW ON "HEPATOCELLULAR CARCINOMA"

Neha Yadav[1], Nidhi Gupta[2]* and Rakesh Bharatia[2]

[1]Institute of Technology & Management Gida Gorakhpur-273209.
[2]ITM College of Pharmacy and Research Gida Gorakhpur-273209.

Article Received on: 03/11/2023
Article Revised on: 23/11/2023
Article Accepted on: 13/12/2023

***Corresponding Author**
Nidhi Gupta
ITM College of Pharmacy and Research Gida Gorakhpur-273209.

ABSTRACT

Hepatocellular carcinoma is a problem for the world's health. a predicted incidence of more than 1 million cases by 2025. With over 90% of cases, hepatocellular carcinoma (HCC) is the most prevalent kind of liver cancer. The main risk factors for HCC development are hepatitis B and C virus infection, while non-alcoholic steatohepatitis linked to metabolic syndrome or diabetes mellitus is increasingly common in the west. Furthermore, HCC with non-alcoholic steatohepatitis-associated molecular pathogensis is distinct. A quarter of all HCCs have potentially treatable mutations that have not yet been applied in clinical settings. When clinical deterioration occurs, HCC is frequently detected, and survival is then assessed as a risk factor. utilizing alfa-fetoprotein (AFP), a serum maker, frequently in conjunction with ultrasound. The accuracy of monitoring is currently being improved by testing a number of other serologic indicators. More advanced imaging techniques, such CT scan and MRI, which have multiphasic contract enhancing capabilities, are frequently needed for the diagnosis of HCC. When serum AFP levels are significantly increased, which happens in less than half of cases at the time of diagnosis, it can be useful to use serum AFP alone. When the diagnosis of HCC is still undetermined, a liver biopsy might be used to confirm the diagnosis. The present requirement for molecular information, which necessitates tissue or liquid biopsies, challenges diagnosis based on non-invasive criteria. The management of patients with advanced HCC has been altered by recent significant developments. Checkpoint inhibitors, tyrosine, and even combinations of two immunotherapy treatments are among the combination medicines that new trials are investigating. The results of these trials are anticipated to alter the HCC management environment at all evolutionary stages.

KEYWORDS: Hepatocellular carcinoma, metabolic syndrome, Stage of liver cancer local disease, liver cirrhosis, Treatment etc.

INTRODUCTION

The diagnosis of hepatocellular carcinoma (HCC) is distinctive in that it frequently relies on noninvasive rather than histological criteria. The well-defined risk groups for its development, bleeding diathesis in cirrhotic patients, technical challenges in some locations, challenges in differentiating between malignant and benign lesions even with a biopsy specimen, and the presence of distinctive serum tumor markers and radiological findings are the justifications behind the preference for noninvasive diagnostic criteria by hepatologists for defining the presence of HCC. However, as the noninvasive diagnostic criteria necessarily include a risk of false-positive HCC diagnosis, noninvasive diagnosis must be used with caution. In general, depending on the goal of the test or criterion and its relative importance, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic likelihood ratios are used to assess the accuracy of a diagnostic test or criterion. For instance, the areas under the sensitivity and 1-specificity curves can be used to calculate the ideal amount of serum alpha-fetoprotein (AFP) during a surveillance program. In other words, the most crucial elements in determining whether a test is effective as a surveillance test are sensitivity with a reasonable specificity trade-off. However, the idea should be modified if serum AFP levels are utilized to definitively diagnose HCC in a patient with a hepatic tumor or nodule Theoretically, there shouldn't be any false-positive cases as the majority of cancer treatments have significant treatment-related morbidities and mortalities and the approach to therapy can vary depending on the type of cancer. As a result, both the specificity and PPV should be extremely near to 100%. In other words, only when the likelihood of HCC is almost 100% may a biopsy be skipped. Since these patients should be biopsied to determine whether they have a hepatic mass,

the NPV is less significant in this scenario. If the test result is negative, for instance, a 100% NPV suggests that the patient does not have HCC; nonetheless, there is still a possibility of a malignant condition other than HCC. Consequently, we might claim that a test or standard is superior to others only if it is possible to boost sensitivity while keeping 100% PPV or specificity. If a test or criterion is assessed under circumstances that do not accurately reflect the true clinical situation for which it is being utilized, bias may result. About 80% of the patients in study 1 received surgical excision or liver transplantation; individuals with numerous tumors were excluded from the trial.

Possible symptoms of liver cancer

The primary signs of liver cancer in patients without the above-described particular surveillance are the following:

- Unexplainable weight loss
- Fatigue
- Loss of appetite or feeling very full after a small meal
- Nausea or vomiting
- Fever
- An enlarged liver, felt as a mass under the ribs on the right side
- An enlarged spleen, felt as a mass under the ribs on the left side
- Pain in the abdomen or near the right shoulder blade
- Swelling or fluid build-up in the abdomen
- Itching
- Yellowing of the skin and eyes (jaundice)
- Enlarged veins on the abdomen that become visible through the skin

All of these symptoms may only be present at an advanced stage of liver cancer or they may be brought on by other illnesses. However, additional investigations should always be taken into account when there is a combination of several of the symptoms mentioned above, especially if they continue. On occasion, when the blood is examined for other reasons, a decline in liver function can be found. Further research should be done because this can be brought on by a variety of different conditions.

Stage of liver cancer

AJCC Stage	Stage group in	Stage description
IA	T1a N0 M0	A single tumor 2 cm (4/5 inch) or smaller that hasn't grown into blood vessels (T1a). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
IB	T1b N0 M0	A single tumor larger than 2cm (4/5 inch) that hasn't grown into blood vessels (T1b). The cancer has not spread to nearby lymph nodes (N0) or to distant sites (M0).
II	T2 N0 M0	Either a single tumor larger than 2 cm (4/5 inch) that has grown into blood vessels, OR more than one tumor but none larger than 5 cm (about 2 inches) across (T2). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
IIIA	T3 N0 M0	More than one tumor, with at least one tumor larger than 5 cm across (T3). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
IIIB	T4 N0 M0	At least one tumor (any size) that has grown into a major branch of a large vein of the liver (the portal or hepatic vein) (T4). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
IVA	Any T N1 M	A single tumor or multiple tumors of any size (Any T) that has spread to nearby lymph nodes (N1) but not to distant sites (M0).
IVB	Any T Any N M1	A single tumor or multiple tumors of any size (any T). It might or might not have spread to nearby lymph nodes (any N). It has spread to distant organs such as the bones or lungs (M1

Liver cancer classification

Doctors can frequently predict a patient's prognosis (outlook) with the aid of formal staging systems (such those previously mentioned). However, for the purpose of therapy, clinicians frequently divide liver tumors into simpler categories based on whether or not they can be totally removed (resected). Resectable refers to the capacity for surgical removal.

Potentially resectable or transplantable cancers

These malignancies can be totally removed surgically or treated with a liver transplant if the patient is healthy enough. This would apply to people without cirrhosis or other significant medical conditions, and would encompass the majority of stage I and some stage II malignancies according to the TNM criteria. This kind of tumor is seen in a very tiny percentage of liver cancer patients.

Unresectable cancers
Unresectable cancers are those that cannot be entirely eliminated by surgery but have not yet spread to distant organs or lymph nodes. This includes malignancies that have spread throughout the liver or that cannot be surgically removed because they are too close to the liver's major arteries, veins, and bile ducts.

Inoperable cancer with only local disease
Although the malignancy is tiny and at the proper location for removal, you are not in good enough health to have surgery. The reason for this is frequently that your non-cancerous liver is unhealthy (due to cirrhosis, for instance), so even after the cancer is removed, your liver may not have enough healthy liver tissue to operate normally. Additionally, it can imply that you have serious health issues that make surgery risky.

Advanced (metastatic) cancers
Advanced cancers are those that have progressed to lymph nodes or other organs. These would include malignancies with TNM stages IVA and IVB. Surgery cannot be used to treat the majority of advanced liver malignancies.

Cause of liver cancer
The majority of the time, cirrhosis of the liver comes before liver cancer. Although only a small portion of people with chronic liver disease will eventually develop liver cirrhosis, this condition is a side effect of chronic liver disease. In cirrhosis, liver tissue slowly changes to become more and more fibrous tissue and scar tissue at the expense of healthy liver cells. Normal cell growth and function are not present in the liver. There is still much to learn about the precise mechanisms and causes of liver cancer. However, the primary form of liver cancer, hepatocellular carcinoma, is most often brought on by cirrhosis and its causes.[1]

A risk factor raises the likelihood that cancer may develop, but it neither precedes nor suffices to cause cancer. It is not an independent cause. Some individuals with these risk factors never develop liver cancer, and some individuals without any of these risk factors nonetheless do so.

The main risk factors are those that lead to cirrhosis, although there are also others that are unrelated to the disease.

Causes of liver cirrhosis: Hepatitis B or C virus (HBV or HCV) infection that is ongoing. When the hepatitis virus stays in the blood for more than six months and impairs liver function, an infection with HBV or HCV is deemed chronic. Hepatitis B infection causes 50% and hepatitis C infection 25% of all liver cancer cases globally, respectively. Chronic hepatitis B infection triples and chronic hepatitis C infection quadruples the chance of developing liver cancer, respectively. Up to 85% of people with hepatitis C experience chronic infection; of these, about 30% proceed to cirrhosis, and in these people, 1 to 2% of people get liver cancer every year The risk is significantly increased by co-infection with HBV, which refers to the simultaneous occurrence of both viruses. Infection with hepatitis B can result in liver cancer without first developing cirrhosis. The virus has the ability to combine its own DNA (deoxyribonucleic acid) with the DNA of a liver cell, resulting in gene alterations in the liver cell. A cell may become unable to govern its regular growth, reproduction, and natural cell death as a result of these alterations. It is commonly accepted that if these processes spiral out of control, cancer may result. The introduction of immunization around the globe is projected to significantly reduce incidence of hepatitis B and liver cancer linked to this virus Antiviral therapy for chronic hepatitis B infection is also expected to decrease liver-related deaths (including liver cancer). Additionally, current research indicates that antiviral therapy may greatly lower the risk of liver cancer in a patient with persistent hepatitis C infections.

Abuse of alcohol over a long period of time can result in liver cancer and cirrhosis. Alcohol is the leading cause of liver cancer in nations with low HBV infection rates. Drinking alcohol while having hepatitis further raises the danger. The risk of getting cirrhosis and liver cancer can be significantly decreased by abstaining from alcohol for an extended period of time. o Some genetic liver disorders, such as haemochromatosis or alpha-1-antitrypsin deficiency, can also lead to cirrhosis. A hereditary condition known as hemochromatosis results in a greater absorption of iron from diet. The iron is then stored in a number of organs, primarily the liver. An aberrant version of the protein alpha1-antitrypsin is accumulated in the liver cells in alpha-1-antitrypsin deficiency. This may result in liver cirrhosis and raise the danger of liver cancer. Cirrhosis and cancer are two disorders affecting the liver that can also be caused by non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. They are not brought on by an infection or heavy drinking, but they do appear to be related to extreme obesity and diabetes. As a result, diabetes and obesity are also considered risk factors for liver cancer. Additionally, the danger is greatly raised if a diabetic patient drinks a lot of alcohol. Adopting a healthy lifestyle can lower the risk of non-alcoholic fatty liver disease and liver cancer by preventing obesity and type 2 diabetes.. Interventions aimed at changing a person's lifestyle can lower this risk in obese or type 2 diabetic individuals. Other, less common medical diseases that affect the liver and raise the risk of cancer exist. Among them are autoimmune hepatitis, Wilson's disease, and intrahepatic biliary inflammations (primary biliary cirrhosis and primary sclerosing cholangitis). Alcohol or an infection are not the causes of these ailments.

Gender: Men are four to eight times more likely than women to get liver cancer, albeit this is likely due to

behavioral differences that alter the previously mentioned risk factors.

Exposure to toxic agents: Some athletes use hormones called anabolic steroids to gain more strength and muscle bulk. The risk of hepatocellular adenoma, a benign liver tumor that can develop into HCC and become malignant*, increases with prolonged use of anabolic steroids. o Consuming food contaminated with aflatoxin: Aflatoxin is a poisonous substance created by a fungus that can develop on food (including peanuts, wheat, soybeans, ground nuts, corn, and rice) when stored in warm, humid conditions. When consumed frequently, it can alter the DNA of liver cells, turning them into cancerous cells. Reduced exposure to foods contaminated with aflatoxin may reduce the incidence of liver cancer, particularly in HBV*-infected individuals.

Other factors although the research is conflicting, factors like smoking have been demonstrated to raise the risk of liver cancer. To confirm these potential risk factors*, more study is required.

Diagnosis

All patients with liver cirrhosis, as well as certain individuals without cirrhosis but with HBV and HCV infections, as mentioned above, require constant monitoring. An ultrasound of the liver should be done every six months to check for any new nodules, cysts, or lumps that could become cancerous.

1. An ultrasound test is used to find nodules, which are typically only detectable through imaging. The next steps are determined by the size and imaging properties of the nodule when it is detected on ultrasound. These two characteristics reveal the likelihood that a nodule will develop into liver cancer. A nodule under 1 cm in size needs to be monitored with ultrasonography every six months. It is unlikely that this kind of nodule would develop into liver cancer in the upcoming months. A CT with contrast, an ultrasound, or an MRI with contrast should be used to study a nodule that is between 1 and 2 cm in size. The nodule should be considered as liver cancer if two separate procedures demonstrate this appearance. If not, the doctor must perform a biopsy or remove the nodule to allow for a laboratory analysis. A biopsy is the process of taking a tissue sample, in this example a small piece of liver tissue, by inserting a thin or thick needle under the skin of the right flank and into the liver. The term "fine needle aspiration" refers to a sample extraction method. A nodule may be removed as part of an operation. Sometimes the likelihood of the diagnosis is so high that a biopsy is not required. The cases listed below should be regarded as liver cancer cases with proof. if a technology for imaging reveals that the nodule is larger than 2 cm and has the appearance of a liver tumor. If the blood's alpha-fetoprotein level (see below) is high (400 ng/ml or more) or keeps rising, there may be a nodule in the liver.

2. A blood test for a protein called alpha-fetoprotein, or AFP, can provide additional details. Normal amounts of AFP are seen in the blood of fetuses, but soon after birth, these levels drop to very low levels and remain there. Adults may develop liver cancer if their blood levels are revealed to be higher than usual. In cirrhotic patients, AFP blood testing may be performed to screen for early tumors. However, because the tests are not always reliable, it is typically not advised to use them for screening in individuals without cirrhosis. There isn't a rise in AFP levels in the blood in a small percentage of liver cancer cases. Also not enhanced in fibrolamellar cancer is the level of AFP. The level of AFP is frequently only increased when liver cancer has already advanced. A high level of AFP may also be present in various diseases or tumors growing in other organs including the testis or ovary, as well as non-cancerous liver ailments. An altered AFP level is frequently reported in cirrhotic patients. Therefore, it is discovered that this test is only beneficial when combined with an ultrasound examination.

3. Radiological examination The liver will first undergo an ultrasound in order to assess the organ's consistency and search for any potential abnormalities. At the time of diagnosis, liver cancer tumors are multilocular in 75% of patients. Multifocal refers to the presence of many nodules (or tumors) in various locations throughout the liver. A CT or MRI scan may also be carried out to obtain a more accurate image and enable the detection of tiny nodules. Patients who already have (benign) nodules because of their cirrhosis can benefit most from an MRI. In order to identify any nodules, these tests are occasionally carried out following an intravenous injection of a contrast fluid. The series of examinations used to identify liver cancer will depend on the size of the lesions and on the presence of cirrhosis seen after the radiological examinations.

4. Histopathological examination A biopsy of liver tissue is used for the histological investigation. A surgeon who specializes in liver surgery should be consulted when deciding whether to undergo a biopsy. Only then can the nature of a lesion discovered during a radiological test be determined. A biopsy can be performed by inserting a thin or thick needle into the liver via the skin of the right flank and removing a sample of the liver tissue. In order to ensure that the needle is inserted directly into a suspected nodule, an ultrasound or CT scan may occasionally be performed concurrently. During a laparoscopic procedure, a surgeon can also obtain a biopsy. In order to view the belly's interior and perform a biopsy without having to make a large incision in the abdomen, the surgeon inserts a small camera and delicate equipment during laparoscopy through one or more small incisions in the skin of the abdomen. A professional called a pathologist will analyze the tissue sample in a lab under a microscope. To determine the precise type and characteristics of the tumor, he may also carry out other testing. Even if the

pathologist determines that there were no cancer cells in the biopsy, it might not be able to rule out the possibility that the tumor is malignant. The procedure carries a risk of bleeding since the liver contains many blood arteries, and patients with cirrhosis may have poor blood coagulation. Additionally, there is a little possibility that a liver biopsy could transmit the disease along the needle's path. It is crucial to reduce this risk if the cancer has not yet spread. When the biopsy is performed with a fine needle, the risk is reduced. When a needle is inserted into a tumor, there is no chance that it may erupt.

5. Treatements

Natural substances and the effects they have on liver cancer Black and long peppers contain the alkaloid piperine, which has anti-tumor, antimutagenic, anti-oxidant, and anti-proliferative properties. The bioavailability of medications and phytochemicals is increased by lowering lipid peroxidation and inhibiting drug metabolism enzymes such aryl hydrocarbon hydroxylase and UDP glucuronyl transferase. In addition, when it interacts with the lipid milieu of the gut, intestinal absorption is improved.

A component of turmeric called curcumin has many biological impacts in a number of disorders, including liver cancer. In rats, curcumin improved piperine's ability to treat diethylnitrosamine-induced HCC. Rats' liver and serum showed signs of synergistic effect since the combination caused less morphological, biochemical, apoptotic, and proliferative alterations than curcumin alone or a placebo.

The primary source of oil in the Mediterranean diet is extra-virgin olive oil, which contains the phenolic component oleocanthal. Extra-virgin olive oil consumption and the likelihood of developing cancer, metabolic, cardiovascular, Alzheimer's, and osteoporosis illnesses are all inversely correlated. Oleocanthal induces apoptosis and destroys cancer cells. Additionally, due to its association with ongoing liver injury and regeneration, chronic inflammation may cause fibrosis, cirrhosis, and HCC. HCC-related inflammation makes liver cancer worse. HCC cells have up-regulated COX-2 in comparison to normal cells, and greater quantities are visible as cancer cells differentiate.[33] Oleocanthal inhibits COX-1 and COX-2 to have anti-inflammatory actions. Oleocanthal inhibited the development of HCC cells more than the NSAIDs and COX inhibitors ibuprofen, indomethacin, and nimesulide. Cleavage of PARP, activation of caspase-3/caspase-7, and chromatin condensation were connected to oleocanthal treatment-induced suppression of colony formation and induction of apoptosis. Increased levels of mitochondrial depolarization and intracellular reactive oxygen species generation were caused by an increase in the expression of the DNA damage indicator H2AX. Oleocanthal exhibited selectivity in that it was harmful to HepG2, Huh7, and Hep3b cells but not to healthy human hepatocytes. Oleocanthal at various doses accelerated caspase and PARP cleavage along with G0/G1 cell cycle arrest. Oleocanthal decreased cell growth by causing cell cycle arrest and apoptosis in HepG2, Huh-7, and Hcclm3 HCC cells but had no discernible impact on normal human (LO2) cells. Oleocanthal inhibited HCC metastasis in vivo and reduced migration and invasion of HCC cells. Survivin, cyclin D1, MMP 2, the Bcl-2 family of proteins, and STAT3 nuclear translocation and DNA binding activity were all decreased by this herbal extract. Additionally, the therapy reduced the positive STAT3 regulators p-JAK1 and p-JAK-2m and elevated the negative STAT3 regulator SHP-1.Epithelial mesenchymal transition (EMT), a factor in metastasis, was suppressed as a result of decreased RNA and protein expression of the transcription factor Twist.

Allium extracts have the ability to prevent tumor growth and are linked to lower cancer risk. These extracts contain a variety of flavanols and organosulfur compounds that prevent different phases of carcinogenesis. Diallyl sulfide, one of the components, prevented the development of hepatocellular adenomas brought on by diethylnitrosamine and hepatocarcinogenesis.

Allyl cysteine (SAC), Another allium extract ingredient showed anti-proliferative properties. The proliferation biomarkers Ki-67 and proliferation cell nuclear antigen were down-regulated in MHCC97L cells treated with SAC, completely inhibiting colony formation. More cells were necrotic or in the early or late stages of apoptosis when SAC was present; this was accompanied by higher levels of caspase-3 and caspase-9 and lower levels of Bcl xL and Bcl-2. It was noticeable that there were more S-phase cells and less G2/M phase cells. Cell cycle proteins (cdc2, cdc25c, and cyclin B1) were suppressed, which confirmed these conclusions. Migration and invasion were decreased in the treated cells. E-cadherin and vascular endothelial growth factor (VEGF) mRNA expression levels increased and decreased, respectively, along with this, two factors linked to metastasis. Animals also experienced metastatic inhibition.[39] HepG2 cells were the only cancer cells to experience a G0/G1 block when allium extracts in methanol were utilized. There was S and G2/M phase arrest in the other cells. Allium bulb extract treatment of cancer cells also led to an increase in apoptotic cells. These cells displayed increased caspase-9 activity as well as p53 expression, a tumor suppressor. An allium extract and the typical cancer chemotherapy medication doxorubicin combined had a synergistic effect that reduced the plasma concentrations required to cause cytotoxicity. HepG2 cells were subject to this impact, but normal cells were not.

The plant Viscum album var (VAV), In Asia, a herb known as the Korean or European mistletoe is utilized to treat chronic liver problems. Herbal extracts promote the growth of healthy liver cells without becoming cytotoxic. At the same doses as for the normal liver cells, there

were anti-proliferative effects on SK-Hep-1 cells. Additionally, there were fewer cancer cells in the S and G2/M stages and more cells in the G0/G1 phases. Additionally, the levels of the S-phase regulator, Cdk2, and cyclin D1 decreased after therapy while p21 gene expression increased. Thus, cell cycle arrest was also seen in addition to the reduction of proliferation. Two congeners isolated from Juglans mandshurica Maxim demonstrated moderate cytotoxicity (compound 4) or 50% cell death (compound 5) for both HepG2 and Hep3B cells. One of its alkaloids demonstrated anti-hepatoma characteristics, including causing autophagic death in Hep3B cells and stimulating apoptosis and autophagy in HepG2 cells. Juglanthraquinone, which was isolated from extracts of Maxim, showed cytotoxic effects and decreased HepG2 cell survival compared to normal L02 cells, making it a promising medication for treating liver cancer. With S phase arrest, decreased G2/M populations, decreased Ki67, cyclin A, and cdk2 expression, and increased Cip1/p21 expression, an anti-proliferative effect was demonstrated. DNA fragmentation, chromatin condensation, activation of caspase-3 and -9, increased levels of Bax, and decreased levels of Bcl-2 all showed signs of apoptosis. Therefore, these natural herbs include substances that are potential therapeutic agents for treating liver cancer.

5-FU, a medication that suppresses cell development at the S-phase and increases p53 levels is used to slow the spread of certain malignancies. Furthermore, 5-FU therapy increases miR-22, which is down-regulated in HCCs and inhibits the proliferation of HepG2 and Huh7 cells more than normal cells. However, chemoresistance to 5-FU is a problem for many malignancies, including liver tumors. HCC cells engage defense autophagy against the medication using long non-coding RNAs. Compared to SK-Hep-1 cells, liver cancer stem cells, which are linked to chemotherapy resistance, have a greater rate of survival, demonstrating their role in the establishment of chemoresistance and tumor growth. Still, by combining 5-FU with other chemotherapies, its effectiveness can be increased. Patients with HCC who received a hepatic arterial infusion of 5-FU and cisplatin had a higher survival rate (14 months) than those who did not (5.2 months). Patients with HCC who have developed sorafenib resistance are currently being enrolled in a clinical trial (NTC02967887) that also administers cisplatin and 5-FU.

Cancers can be treated by modifying the immune systems by enhancing immune activity by blocking immune checkpoints responsible for immunosuppressive signaling, by cancer vaccines to prevent infection or inflammatory responses, and by non-specific cancer immunotherapies that boost immune function generally. of patients so that they recognize specific antigens on cancer cells. The American Society of Clinical Oncology named this area of study the Advance of the Year in 2013. The ability to combine immunotherapy with medications now used to treat liver cancer to produce a combined/synergistic impact is a benefit of this field of study. The monoclonal antibodies (mAbs) ramucirumab, which targets VEGF receptor-2, and bevacizumab, which prevents VEGF receptor binding, are currently being tested in clinical trials as part of combination therapy with chemotherapeutic, immunotherapeutic, or other cancer-treating drugs (NCT00410956, NCT01180959, NCT01246986). PD-L1 can be thought of as a biomarker as a result. When patients have high levels of PD-L1, T-cell evasion is facilitated. Patients with high PD-L1 expression (PD-L1 positive) have a worse prognosis than those with low PD-L1 expression (PD-L1 negative). Additionally, PD-L1 positive individuals have more tumors with vascular invasion and are twice as likely to experience relapse as PD-L1 negative patients. As shown by the triple combination of anti-PD-1, anti-CXCR4, and sorafenib, which inhibits metastasis and HCC growth, immunosuppression improves therapeutic outcomes. Hepatitis B and C infections, which are risk factors for HCC, may be decreased by targeting the PD-L1/PD-1 blockade. This treatment may stop relapses because these viral infections are partly to blame for the recurrence of HCC. There is a potential link between autoimmune liver illnesses, primary biliary cirrhosis, and chronic hepatitis type C. Autoimmune disease, however, may arise as a result of an overactive immune system that bypasses the PD-1/PD-L1 and PD-L2 systems. Despite this risk, patients' immune systems are strengthened by these checkpoint inhibitors, which also fight cancer cells, and they seldom manifest autoimmune disorders. Nivolumab, a PD-1 checkpoint inhibitor, has consequently demonstrated good outcomes and has received FDA approval for the treatment of a variety of malignant neoplasms, including HCC. Nivolumab, a CTLA-4 negative regulator, is being used with ipilimumab in a clinical trial for HCC. Ipilimumab was previously approved by the FDA for the treatment of melanoma, colorectal cancer, and renal cell carcinoma (NCT01658878).

Liver transplantation

When excision of the tumor is not an option, liver transplantation should be considered if there is a single tumor with a diameter of less than 5 cm or if there are 2 to 3 tumors, each with a diameter of less than 3 cm. The Milan criteria are what are known as those conditions. the requirements for registering as a potential liver transplant candidate for those with liver cancer Due to a lack of eligible donor livers, transplantation is only feasible under very rigorous guidelines. The patient must first satisfy the aforementioned Milan requirements.a relation to the quantity and size of liver tumors. Different nations have different laws governing liver donors and transplants. You can get country-specific details by speaking with a doctor or other liver professionals transplantation. Donor livers typically originate from individuals who have recently passed away or have been declared "brain dead." Brain-dead refers to a condition in which breathing and blood circulation can only be supported by medical technology since the brain has

suffered from oxygen deprivation and will never be able to operate normally again. Again, rules particular to each country specify exactly when and how someone might be pronounced brain dead. The patient must first be determined to be in good enough health for the procedure because these circumstances are rare and not every patient can receive a donor liver. Additionally, his or her general prognosis must be favorable enough to be added to the waiting list. Patients with liver cirrhosis brought on by alcohol consumption who continue to drink as well as those with a bad prognosis because of the characteristics of their malignancy or because of other concomitant diseases will not be given transplant consideration. Split-liver transplants, which involve giving each patient a portion of a donor liver, marginal graft transplants, or live donor liver transplants, which involve giving the patient a portion of a healthy living donor's liver, are all procedures that some centers with a lot of experience can perform. Since these are rare circumstances, both the hospital's transplant advisory board and the ethics committee must assess each patient's chances of success.

A liver transplant is a surgical procedure performed under general anesthesia that typically lasts 6 to 10 hours. The old liver of the patient will next be removed, leaving some of the major recipient blood arteries in place, after the doctors make a boomerang-shaped incision on the upper region of the belly. The patient's bile ducts and these blood vessels will then be connected to the new liver, which will then be implanted.

treatment options for liver transplant candidates for liver transplants face lengthy waiting periods due to an organ shortage, but this should not stop the conversation about an effective alternative therapy. Patients may be offered resection, local ablation, or transarterial chemoembolization in the event that a lengthy expected waiting period (>6 months) exists in order to reduce the risk of tumor progression and provide a "bridge" to transplant. This guide goes on to provide information on local ablation and trans-arterial chemoembolization procedures.

Radiotherapy- External beam radiation therapy can reduce extrahepatic metastases and produce radiological responses in HCC liver tumors of various sizes and stages. Prospective investigations of stereotactic body radiation therapy with photons or protons in patients with HCC liver-confined tumors reveal significant rates of radiological responses with acceptable safety in primarily Child-Pugh A groups, albeit these results are constrained by uncontrolled study designs. A combined analysis of 102 patients who received photon stereotactic body radiation therapy from 24 to 54 Gy over six fractions for unresectable HCC with Child-Pugh A liver function found objective responses in 54% of patients and a median overall survival of 17 months. Better results have been observed in this population232 as well as in HCC lesions with cancer macrovascular invasion in other, smaller, uncontrolled investigations. Due of selection bias and population heterogeneity, most research comparing radiation with other locoregional therapies in HCC are retrospective in nature. With a hazard ratio of 0.52 (95% CI 0.26-1.05) for 2-year liver progression-free survival (PFS)nts and a median overall survival of 17 months, the randomized phase III APROH trial comparing proton beam radiotherapy to RFA under a non- inferiority design involved 144 patients with small HCC tumours (i.e., up to 2 tumours 3 cm) and well-preserved liver function. Collectively, these trials suggest that radiotherapy may have a place in certain patients' treatment plans, especially for those who have small tumors that cannot be removed surgically or transplanted. To determine the ideal radiation modality and to validate whether these techniques are similar to RFA, more randomized studies with extended follow-up and pooled analysis are needed.

REFERENCE

1. American Cancer Society. Cancer Facts & Figures. Atlanta, Ga: American Cancer Society, 2023.
2. SEER*Explorer: An interactive website for SEER cancer statistics [Internet] Surveillance Research Program, National Cancer Institute. Accessed at https://seer.cancer.gov/explorer/ on February 23, 2023.
3. National Cancer Institute. Physician Data Query (PDQ). Adult Primary Liver Cancer Treatment. Accessed at www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq on February 1, 2019.
4. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl, 2009; 15(6): 574-580.
5. Bae SY, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, et al. Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area.
6. Clin Mol Hepatol, 2012; 18: 185-194. 2. Choi JY, Lee HC, Yim JH, Shim JH, Lim YS, Shin YM, et al. Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis. J Gastroenterol Hepatol, 2011; 26: 1004-1009.
7. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology, 2008; 47: 97-104.
8. Yang B, Chen WH, Li QY, Xiang JJ, Xu RJ. Hepatic angiomyolipoma: dynamic computed tomography features and clinical correlation. World J Gastroenterol, 2009; 15: 3417-3420.
9. Vilana R, Forner A, Bianchi L, García-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular

carcinoma on contrast-enhanced ultrasound. Hepatology, 2010; 51: 2020-2029.
10. Kim SE, Lee HC, Shim JH, Park HJ, Kim KM, Kim PN, et al. Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area. Liver Int., 2011; 31: 1468-1476.
11. Isonishi S, Ogura A, Kiyokawa T, Suzuki M, Kunito S, Hirama M, et al. Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman. Int J Clin Oncol, 2009; 14: 70-73.
12. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology, 2011; 53: 1020-1022.
13. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev, 2006; 15: 1198-120.
14. Park JW, Choi JY, Seo KS. 2009 Hepatocellular carcinoma practice guideline. Seoul: The Korean Liver Cancer Study Group and the Na tional Cancer Center, 2009; 1-56.
15. Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst., 2009; 101: 296-305.
16. Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a metaanalysis. Ann Oncol, 2013; 24: 301-8.
17. Batty GD, Shipley MJ, Jarrett RJ, et al. Obesity and overweight in relation to organspecific cancer mortality in London (UK): findings from the original Whitehall study Int J Obes (Lond), 2005; 29: 1267-74.
18. Batty GD, Shipley MJ, Kivimaki M, et al. Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. Int J Obes (Lond), 2008; 32: 1741-4.
19. Batty GD, Barzi F, Huxley R, et al. Obesity and liver cancer mortality in Asia: The Asia Pacific Cohort Studies Collaboration. Cancer Epidemiol, 2009; 33: 469-72.
20. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA Cancer J Clin, 2019; 69: 734.
21. B.Q. Starley, C.J. Calcagno, S.A. Harrison, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, Hepatology (Baltimore, Md.), 2010; 51: 18201832.
22. M.M. Center, A. Jemal, International trends in liver cancer incidence rates, Cancer Epidemiol Biomarkers Prev, 2011; 20: 2362-2368.
23. H.B. El-Serag, J.A. Marrero, L. Rudolph, K.R. Reddy, Diagnosis and treatment of hepatocellular carcinoma, Gastroenterology, 2008; 134: 1752-1763.
24. Soerjomataram, D. Oomen, V. Lemmens, A. Oenema, V. Benetou, A. Trichopoulou, J.W. Coebergh, J. Barendregt, E. de Vries, Increased consumption of fruit and vegetables and future Cancer incidence in selected European countries, Eur J Cancer, 2010; 46: 2563-2580.
25. S. Banerjee, S.K. Singh, I. Chowdhury, J.W. Lillard, Jr., R. Singh, Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer Front Biosci (Elite Ed), 2017; 9: 235-245.
26. S.K. Singh, S. Banerjee, E.P. Acosta, J.W. Lillard, R. Singh, Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway, Oncotarget, 2017; 8: 17216-17228.
27. X. Li, R. Sun, R. Liu, Natural products in licorice for the therapy of liver diseases: Progress and future opportunities, Pharmacol Res, 2019; 144: 210-226.
28. Y. Zhou, Y. Li, T. Zhou, J. Zheng, S. Li, H.B. Li, Dietary Natural Products for Prevention and Treatment of Liver Cancer, Nutrients, 2016; 8: 156.
29. R.K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S.K. Gupta, M.F. Fromm, Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 J Pharmacol Exp Ther, 2002; 302: 645-650.
30. M. Ren, L. Ye, X. Hao, Z. Ren, S. Ren, K. Xu, J. Li, Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition,J Tradit Chin Med, 2014; 34: 309-316.
31. S.B. Coffelt, K.E. de Visser, Revving Up Dendritic Cells while Braking PD-L1 to JumpStart the Cancer-Immunity Cycle Motor, Immunity, 2016; 44: 722-724.
32. T. Boon, P.G. Coulie, B.J. Van den Eynde, P. van der Bruggen, Human T cell responses against melanoma, Annu Rev Immunol, 2016; 24: 175-208.
33. G, Matthews CE, Moore SC, et al. The association between frequency of vigorous physical activity and hepatobiliary cancers in the NIH-AARP Diet and Health Study. Eur J Epidemiol, 2013; 28: 55-66.
34. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer, 2012; 131: 193-200.
35. Bravi F, Bosetti C, Tavani A, et al. Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-Analysis. Clin Gastroenterol Hepatol, 2013.
36. Brunner RL, Wactawski-Wende J, Caan BJ, et al. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer, 2011; 63: 827-41.
37. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003; 348: 1625-38.
38. Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 1996; 24: 38-42.

39. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008; 135: 111-21.
40. Chen Y, Wang X, Wang J, et al. Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. Eur J Cancer, 2012; 48: 213745.
41. Chen Z, Yang G, Offer A, et al. Body mass index and mortality in China: a 15-year prospective study of 220 000 men. Int J Epidemiol, 2012; 41: 472-81.
42. Bruno, T. C. New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature, 2020; 577: 474–476.
43. Schneider, C. et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut, 2012; 61: 1733–1743.
44. Sautès- Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer, 2019; 19: 307–325.
45. Calderaro, J. et al. Intra- tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J. Hepatol, 2019; 70: 58–65.
46. Finkin, S. et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol, 2015; 16: 1235–1244.
47. Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol, 2017; 14: 397–411.